<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063218</url>
  </required_header>
  <id_info>
    <org_study_id>BR.09.001</org_study_id>
    <nct_id>NCT01063218</nct_id>
  </id_info>
  <brief_title>Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application</brief_title>
  <official_title>Phase IV - Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Brasil Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Brasil Ltda.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this present study is evaluate the decreasing of necessity of topic
      corticoids usage to control outbreaks of light to moderate atopic dermatitis by using the
      correct emollients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical evaluation</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 8, 10, 12, 16, 20 and 24</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Emollient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Only one arm: Emollient (Cetaphil Advanced) to be applied twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Emollient - Cetaphil Advanced</intervention_name>
    <description>Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.</description>
    <arm_group_label>Emollient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female patients

          -  2 to 10 years old.

          -  with light to moderate with no signs of acute/ sub-acute eczema or in activity.

          -  Subjects can not present inflammatory lesions, erythema, edema, eschar, excoriation
             and lichens.

          -  Subjects can present light to moderate dryness.

        Exclusion Criteria:

          -  Subjects presenting any serious systemic disease

          -  Subjects with medical history regarding serious asthma

          -  Subjects with known or suspected allergy to one of the investigational products

          -  Subjects with acute atopic eczema or in activity, needing systemic antibiotics

          -  Subjects with signs of active infections on skin

          -  Subjects whose parents or legal guardian seem to have difficulty in understand the
             informed consent form (ICF)

          -  Female subjects who are not in pre-menarche period.

          -  Subjects who need topic corticoids or any other medication that can interfere on
             Atopic Dermatitis during the study.

          -  Patient with a wash-out period for treatment less than:

          -  injectable corticoids: 60 days

          -  systemic corticoids: 15 days

          -  topic corticoids: 8 days

          -  topic immunomodulator: 8 days

          -  antihistaminic : 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario C Pires, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complexo Hospitalar Padre Bento de Guarulhos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Izelda Costa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitário de Brasília</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitário de Brasília</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <zip>70910-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalar Padre Bento de Guarulhos</name>
      <address>
        <city>Guarulhos</city>
        <state>Sao Paulo</state>
        <zip>07051-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2010</study_first_posted>
  <last_update_submitted>March 9, 2012</last_update_submitted>
  <last_update_submitted_qc>March 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2012</last_update_posted>
  <responsible_party>
    <name_title>Mario Cézar Pires</name_title>
    <organization>Complexo Hospitalar Padre Bento de Guarulhos</organization>
  </responsible_party>
  <keyword>Dermatitis, Atopic</keyword>
  <keyword>Corticoids, topic</keyword>
  <keyword>Corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emollients</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

